Pregnancy in sickle cell trait: what we do and don't know.
Samuel WilsonPatrick EllsworthNigel S KeyPublished in: British journal of haematology (2020)
Sickle cell trait (SCT) is the carrier state for sickle cell disease that results from the HBB rs334 missense mutation (p.Glu6Val) in the β-globin chain of haemoglobin. While not associated with any impact on life expectancy, it has been established that SCT is associated with an increased risk of both venous thromboembolism (and in particular, pulmonary embolism) and chronic kidney disease. It is largely unknown what short- or long-term effect, if any, pregnancy has upon the risk or outcomes of these disorders. In addition, SCT has been linked with various adverse outcomes in pregnancy, ranging from maternal complications such as elevated risk of bacteriuria to potentially life-threatening entities such as pre-eclampsia and prematurity. In these scenarios also, no clear association with SCT has been established. Given the high worldwide prevalence of SCT, further studies addressing these issues are warranted.
Keyphrases
- pulmonary embolism
- sickle cell disease
- pregnancy outcomes
- venous thromboembolism
- preterm birth
- chronic kidney disease
- risk factors
- inferior vena cava
- genome wide
- pregnant women
- climate change
- preterm infants
- low birth weight
- end stage renal disease
- birth weight
- gene expression
- direct oral anticoagulants
- insulin resistance
- peritoneal dialysis